Resistance to osimertinib, a third-generation tyrosine kinase inhibitor targeting EGF receptor used as first-line therapy for patients with non-small cell lung cancer (NSCLC) harboring mutant EGFR, is mediated by IGF-1R signaling activated by IGF-2 in NSCLC cell lines (41). The gene discussed is IGF2; the disease is non-small cell lung carcinoma.